Skip to main content

Table 4 Comparative analysis of the therapeutic effect of UCMSCs in group A vs group C and group B vs group D at different time points

From: Enhanced therapeutic effects of umbilical cord mesenchymal stem cells after prolonged treatment for HBV-related liver failure and liver cirrhosis

Outcome Group W0–W1 W1–W4 W4–W12 W12–W24
Value P value Value P value Value P value Value P value
ALT Group A 37.5 (5.25–214) NS 5 (− 6 to 42) NS 8 (− 1.25 to 23.5) NS − 3 (− 11 to 5) NS
Group C 19 (2–48) − 0.5 (− 9.3 to 10.25) 2.5 (− 0.5 to 11) − 4 (− 12 to 60)
Group B 24 (9–260) 0.042 22.5 (6.2–45.3) NS − 6 (− 15 to 6) NS 0.5 (− 4 to 5.5) NS
Group D 12.5 (− 0.5 to 98.5) 9.5 (− 0.75 to 9.5) − 6 (− 24.5 to 3.5) 5.5 (0.25–7)
AST Group A 17 (− 5.5 to 60.25) NS − 1 (− 17 to 11) NS 26 (6–53.5) NS 9 (− 5 to 20) NS
Group C 13 (4–28) − 7.5 (− 16.75 to 17) 26 (7.5–40.25) − 3 (− 15 to 9)
Group B 24 (− 10 to 52) NS 16 (− 1 to 43.75) NS 1 (− 15 to 22) NS 3 (− 0.25 to 14.5) NS
Group D 4 (− 4 to 33.75) 7.5 (− 7 to 21.25) 4 (− 11.5 to 9) 8.5 (3.25–17)
PTA Group A 4 (− 1.75 to 6) NS − 1 (− 7 to 3.5) NS − 7 (− 15.5 to 0.5) NS − 3 (− 5.7 to 2.1) NS
Group C 5 (− 4 to 7) − 1 (− 7 to 2.5) − 7 (− 11.75 to 1.5) − 2 (− 4.1 to 1.9)
Group B − 2 (− 4 to 3) NS − 5 (− 12 to − 1) NS − 15 (− 22.5 to − 4.75) NS − 4 (− 7.2 to 1.9) NS
Group D − 2 (− 8 to 1) − 10 (− 19 to − 4) − 4 (− 14.5 to 5) − 3 (− 5.2 to 2.6)
MELD Group A − 1 (− 2 to 1) NS 1 (− 1 to 2.5) NS 6.11 ± 5.32 NS 2.14 ± 1.71 NS
Group C 0 (− 1 to 2) 1 (− 1 to 3) 4 (0.5–7) 2.4 (0.1–5.3)
Group B 1 (− 1 to 2) NS 4 (2–6) NS 6.86 ± 5.01 NS 1.96 ± 1.64 NS
Group D 2 (0–4) 4 (1–6.5) 0.5 (− 0.75 to 5.5) 3.3 (− 0.5 to 4.9)
  1. NS nonsignificant, ALT alanine aminotransferase, AST glutamic-oxaloacetic transaminase, TBIL total bilirubin, PTA prothrombin time activity, MELD model for end-stage liver disease